Antibiotic resistance (ABR) is causing increased mortality and morbidity and is straining the healthcare system. The rising problem of ABR can be controlled through effective antibiotic stewardship system and by facilitating new drug developments. Several new antibiotics are in the pipeline to fight the ABR pandemic. Most of these antibiotics are based on the pre-existing antibiotics. The number of new antibiotics in the pipeline that are active against the multi drug resistant Pseudomonas aeruginosa and Carbapenam resistant Enterobacteriaceae are very limited. This is a very important challenge because there is an acute deficit of antibiotics against the priority pathogens. Similarly, new drugs against hospital acquired pneumonia is also very limited. The various new drugs in the pipeline are Delafloxacin, Meropenam- vaborbactum combination, Imipenem–cilastatin + relebactam, Plazomicin, Eravacycline, Omadacycline, Lefamulin, Cefiderocol, Levonadifloxacin/alalevonadifloxacin to name a few.
To learn more about the new drugs in the pipeline, their mechanism of action, activity spectrum, indications and contraindications and development status, please visit the website of the journal of infection (Link).